Yumanity Therapeutics Profit Margin

Yumanity Therapeutics (YMTX) currently reports a profit margin of -177.46% as of March 2025. That compares with -2173.27% in the prior-year period — up 91.8% year over year. That is below the Healthcare sector average of 13.45%. Use the charts on this page to explore Yumanity Therapeutics's profit margin history and peer comparisons.

Yumanity Therapeutics's profit margin increased from -2173.27% to -177.46% — a 91.8% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Yumanity Therapeutics's profit margin of -177.46% is lower than the Healthcare sector average of 13.45%. That is roughly 1419.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Yumanity Therapeutics's current -177.46% should be judged against Healthcare norms (sector average: 13.45%) and against YMTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -177.46%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.45%. From there, open related valuation or income-statement pages for Yumanity Therapeutics, and consider following YMTX for alerts when major investors trade the stock.